Lei Mao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lei Mao has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Cuiping Meng
2 shared publicationsFeifei Sun
2 shared publicationsJuan Wang
2 shared publicationsSuying Lu
2 shared publicationsYanpeng Wu
2 shared publicationsYi Que
2 shared publications
Latest Publications
- Open Access
- 10 September 2026
- Published by Elsevier in SSRN Electronic Journal
Apatinib Combined with Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma Followed by Apatinib Maintenance Therapy (AIT-NB-01): A Multicentre, Single-Arm, Phase 1/2 Trial
Background: Relapsed or refractory neuroblastoma remains a major therapeutic challenge. Apatinib is an oral multi-target tyrosine kinase inhibitor mainly targeting vascular endothelial growth factor receptor 2 (VEGFR-2). We evaluated the safety, efficacy, and pharmacokinetics of apatinib combined with irinotecan and temozolomide in patients with relapsed or refractory neuroblastoma.Methods: AIT-NB-01 is a multicentre, single-arm, phase 1/2 trial conducted across five centres in China. Patients aged ≥2 years with relapsed or refractory high-risk neuroblastoma were eligible for this study. In phase 1, apatinib (150, 300, or 450 mg/m2) combined with irinotecan (50 mg/m2 intravenously, days 1–5) and temozolomide (150 mg/m2 intravenously, days 1–5) was evaluated using a 3+3 design. In phase 2, patients received apatinib at the recommended phase 2 dose (RP2D) for up to eight cycles, followed by apatinib maintenance until disease progression or unacceptable toxicity. The primary endpoint were the maximum tolerated dose, RP2D and dose-limiting toxicity in phase 1, and best objective response rate (ORR) at the RP2D in phase 2. This completed trial has been registered with ClinicalTrials.gov (NCT05027386).Findings: Between September 2021 and September 2024, 111 patients were enrolled (23 in phase 1; 88 in phase 2). The RP2D of apatinib was 300 mg/m2. Among 96 patients eligible for efficacy at the RP2D, 53 achieved an objective response (ORR: 55%, 95% confidence interval [CI]: 45–65). At a median follow-up of 24·9 months (interquartile range: 16·5–32·9), the median progression–free survival (PFS) was 11·7 (95% CI 10·4–16·6) months. Patients who received apatinib maintenance therapy had significantly longer PFS (median: 16·6 vs. 10·6 months; hazard ratio: 0·61, 95% CI: 0·37–1·00; p=0·0478). Grade 3–4 adverse events occurred in 68 (61%) patients, of which the most common were leukopenia (27%), neutropenia (25%), and thrombocytopenia (20%). Two serious treatment-related adverse events and no treatment-related deaths were reported.Interpretation: Apatinib combined with irinotecan and temozolomide demonstrated promising efficacy with a manageable safety profile in patients with relapsed or refractory neuroblastoma. Oral apatinib maintenance therapy was associated with improved PFS. Further evaluation in randomised controlled trials is warranted.
- 10 September 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessApatinib Combined with Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma Followed by Apatinib Maintenance Therapy (AIT-NB-01): A Multicentre, Single-Arm, Phase 1/2 Trial
Background: Relapsed or refractory neuroblastoma remains a major therapeutic challenge. Apatinib is an oral multi-target tyrosine kinase inhibitor mainly targeting vascular endothelial growth factor receptor 2 (VEGFR-2). We evaluated the safety, efficacy, and pharmacokinetics of apatinib combined with irinotecan and temozolomide in patients with relapsed or refractory neuroblastoma.Methods: AIT-NB-01 is a multicentre, single-arm, phase 1/2 trial conducted across five centres in China. Patients aged ≥2 years with relapsed or refractory high-risk neuroblastoma were eligible for this study. In phase 1, apatinib (150, 300, or 450 mg/m2) combined with irinotecan (50 mg/m2 intravenously, days 1–5) and temozolomide (150 mg/m2 intravenously, days 1–5) was evaluated using a 3+3 design. In phase 2, patients received apatinib at the recommended phase 2 dose (RP2D) for up to eight cycles, followed by apatinib maintenance until disease progression or unacceptable toxicity. The primary endpoint were the maximum tolerated dose, RP2D and dose-limiting toxicity in phase 1, and best objective response rate (ORR) at the RP2D in phase 2. This completed trial has been registered with ClinicalTrials.gov (NCT05027386).Findings: Between September 2021 and September 2024, 111 patients were enrolled (23 in phase 1; 88 in phase 2). The RP2D of apatinib was 300 mg/m2. Among 96 patients eligible for efficacy at the RP2D, 53 achieved an objective response (ORR: 55%, 95% confidence interval [CI]: 45–65). At a median follow-up of 24·9 months (interquartile range: 16·5–32·9), the median progression–free survival (PFS) was 11·7 (95% CI 10·4–16·6) months. Patients who received apatinib maintenance therapy had significantly longer PFS (median: 16·6 vs. 10·6 months; hazard ratio: 0·61, 95% CI: 0·37–1·00; p=0·0478). Grade 3–4 adverse events occurred in 68 (61%) patients, of which the most common were leukopenia (27%), neutropenia (25%), and thrombocytopenia (20%). Two serious treatment-related adverse events and no treatment-related deaths were reported.Interpretation: Apatinib combined with irinotecan and temozolomide demonstrated promising efficacy with a manageable safety profile in patients with relapsed or refractory neuroblastoma. Oral apatinib maintenance therapy was associated with improved PFS. Further evaluation in randomised controlled trials is warranted.
- 26 June 2026
- Published by Wiley in International Journal of Cancer
- Vol. 159 (11) , 2778-2790
Targeted Therapy and Oral Chemotherapy as Maintenance Treatment in Pediatric Very‐High‐Risk and High‐Risk Rhabdomyosarcoma: A Retrospective Study of Efficacy and Safety
Maintenance therapy (MT) and targeted drugs have improved the survival of patients with high‐risk rhabdomyosarcoma (RMS) in clinical trials. However, there are limited data concerning targeted drugs and oral chemotherapy for MT in pediatric patients with very‐high‐risk (VHR) and high‐risk (HR) RMS. Here, we evaluated the safety and effectiveness of these regimens and aimed to identify circulating tumor DNA (ct‐DNA) markers associated with prognosis. We retrospectively retrieved data for 102 pediatric patients with VHR or HR RMS who underwent MT at Sun Yat‐sen University Cancer Center from January 2011 to March 2025 involving targeted drugs plus oral chemotherapy (subgroup 1); targeted drugs (subgroup 2); and oral chemotherapy (subgroup 3). Ct‐DNA markers were examined throughout treatment and at follow‐up. Subgroups 1 and 2 comprised 14 and seven VHR RMS patients, respectively, and subgroup 3 consisted of 39 VHR and 42 HR RMS patients. With a median follow‐up of 32 months, no significant differences among subgroups in duration of remission ( p = 0.56) or 2‐year event‐free survival ( p = 0.78) were observed. PAX–FOXO1 fusion ( p = 0.01), CDK4 mutation ( p = 0.02), and TP53 mutation ( p = 0.02) were independently associated with unfavorable duration of remission. No grade 3 or higher treatment‐related adverse events were observed. MT with targeted drugs shows comparable efficacy in VHR and HR pediatric RMS patients, with manageable adverse reactions. Longitudinal ct‐DNA testing could guide treatment decision‐making and prognostic stratification for these patients.
- 26 June 2026
- Published by Wiley in International Journal of Cancer
- Vol. 159 (11) , 2778-2790
Targeted Therapy and Oral Chemotherapy as Maintenance Treatment in Pediatric Very‐High‐Risk and High‐Risk Rhabdomyosarcoma: A Retrospective Study of Efficacy and Safety
Maintenance therapy (MT) and targeted drugs have improved the survival of patients with high‐risk rhabdomyosarcoma (RMS) in clinical trials. However, there are limited data concerning targeted drugs and oral chemotherapy for MT in pediatric patients with very‐high‐risk (VHR) and high‐risk (HR) RMS. Here, we evaluated the safety and effectiveness of these regimens and aimed to identify circulating tumor DNA (ct‐DNA) markers associated with prognosis. We retrospectively retrieved data for 102 pediatric patients with VHR or HR RMS who underwent MT at Sun Yat‐sen University Cancer Center from January 2011 to March 2025 involving targeted drugs plus oral chemotherapy (subgroup 1); targeted drugs (subgroup 2); and oral chemotherapy (subgroup 3). Ct‐DNA markers were examined throughout treatment and at follow‐up. Subgroups 1 and 2 comprised 14 and seven VHR RMS patients, respectively, and subgroup 3 consisted of 39 VHR and 42 HR RMS patients. With a median follow‐up of 32 months, no significant differences among subgroups in duration of remission ( p = 0.56) or 2‐year event‐free survival ( p = 0.78) were observed. PAX–FOXO1 fusion ( p = 0.01), CDK4 mutation ( p = 0.02), and TP53 mutation ( p = 0.02) were independently associated with unfavorable duration of remission. No grade 3 or higher treatment‐related adverse events were observed. MT with targeted drugs shows comparable efficacy in VHR and HR pediatric RMS patients, with manageable adverse reactions. Longitudinal ct‐DNA testing could guide treatment decision‐making and prognostic stratification for these patients.